The ethics and economics of pharmaceutical pricing
- PMID: 25149920
- DOI: 10.1146/annurev-pharmtox-010814-124649
The ethics and economics of pharmaceutical pricing
Abstract
The cost of drugs is a major and rapidly rising component of health-care expenditures. We survey recent literature on the ethics and economics of skyrocketing pharmaceutical prices and find that advances in economic research have increased the sharpness and focus of the ethically based calls to increase access by modifying patent protection and reducing prices. In some cases, research supports ethical arguments for broader access. Other research suggests that efforts to broaden access result in unintended consequences for innovation and the medical needs of patients. Both ethicists and economists need to be more cognizant of the real clinical settings in which physicians practice medicine with real patients. Greater cross-disciplinary interaction among economists, ethicists, and physicians can help reduce the disjunction between innovation and access and improve access and patient care. This dialogue will impact private industry and may spur new multistakeholder paradigms for drug discovery, development, and pricing.
Keywords: differential pricing; drug access; innovation; patents; prescribing; price controls; rationing.
Similar articles
-
Pharmaceuticals and medical devices: business practices.Issue Brief Health Policy Track Serv. 2013 Dec 30:1-36. Issue Brief Health Policy Track Serv. 2013. PMID: 24482889 No abstract available.
-
Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.Seton Hall Law Rev. 2011;41(2):625-69. Seton Hall Law Rev. 2011. PMID: 21739760 No abstract available.
-
Should the patent system for pharmaceuticals be replaced? A theoretical approach.Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):617-26. doi: 10.1586/14737167.2014.927315. Epub 2014 Jun 17. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 24934980 Review.
-
Pharmaceuticals and medical devices: business practices. End-of-year issue brief.Issue Brief Health Policy Track Serv. 2010 Jan 4:1-58. Issue Brief Health Policy Track Serv. 2010. PMID: 20213918 No abstract available.
-
The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.Nurs Econ. 2005 Nov-Dec;23(6):307-11, 279. Nurs Econ. 2005. PMID: 16459902 Review.
Cited by
-
Variables affecting new drug prices in South Korea's pricing system.Front Pharmacol. 2024 May 9;15:1370915. doi: 10.3389/fphar.2024.1370915. eCollection 2024. Front Pharmacol. 2024. PMID: 38783941 Free PMC article.
-
Cost sharing in managed care and the ethical question of business purpose.J Manag Care Spec Pharm. 2023 Aug;29(8):965-969. doi: 10.18553/jmcp.2023.29.8.965. J Manag Care Spec Pharm. 2023. PMID: 37523316 Free PMC article.
-
Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.Syst Rev. 2022 Dec 1;11(1):257. doi: 10.1186/s13643-022-02114-z. Syst Rev. 2022. PMID: 36457058 Free PMC article.
-
The impact of drug shortages on drug prices: evidence from China.Front Public Health. 2023 Nov 8;11:1185356. doi: 10.3389/fpubh.2023.1185356. eCollection 2023. Front Public Health. 2023. PMID: 38026336 Free PMC article.
-
The Imperative of Regulation: The Co-creation of a Medical and Non-medical US Opioid Crisis.Psychoactives. 2023 Nov 3;2(4):317-336. doi: 10.3390/psychoactives2040020. Psychoactives. 2023. PMID: 39280929 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
